{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Trusha Adeshara",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright Â© 2019 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function",
      "version": "1.0.0"
    },
    "namespace_pattern": {
      "NCIT": "^C\\d+$",
      "PUBCHEM": "^\\d+$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/3c93a65dc48e6786fe29ae55aa36cf9a902fe8c6/export/conso-names.belns",
      "DOID": "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns",
      "EFO": "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns",
      "HP": "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/hp-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/conso/f02c6ad4a4791a8ed45448513b9de8c8f1b00c87/external/mesh-names.belns"
    },
    "path": "ms/ontaneda2016.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Patients with primary and secondary progressive multiple sclerosis exhibit gradually worsening disability, most often motor impairment with a pattern suggesting a myelopathy, but also progressive hemiparesis, ataxia, visual dysfunction, or cognitive impairment.",
      "key": "6f13af5c1404da002d898fcaceddeaad",
      "line": 79,
      "relation": "increases",
      "source": 35,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Patients with primary and secondary progressive multiple sclerosis exhibit gradually worsening disability, most often motor impairment with a pattern suggesting a myelopathy, but also progressive hemiparesis, ataxia, visual dysfunction, or cognitive impairment.",
      "key": "68dc0a045c4278607f000d8516cf11e4",
      "line": 81,
      "relation": "increases",
      "source": 35,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Patients with primary and secondary progressive multiple sclerosis exhibit gradually worsening disability, most often motor impairment with a pattern suggesting a myelopathy, but also progressive hemiparesis, ataxia, visual dysfunction, or cognitive impairment.",
      "key": "dd32b1ca6b4f480a0c48ae9f274d486b",
      "line": 83,
      "relation": "increases",
      "source": 35,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Patients with primary and secondary progressive multiple sclerosis exhibit gradually worsening disability, most often motor impairment with a pattern suggesting a myelopathy, but also progressive hemiparesis, ataxia, visual dysfunction, or cognitive impairment.",
      "key": "a70ee2fa2da5b7c1b418da1fe81a7aa7",
      "line": 85,
      "relation": "increases",
      "source": 35,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Patients with primary and secondary progressive multiple sclerosis exhibit gradually worsening disability, most often motor impairment with a pattern suggesting a myelopathy, but also progressive hemiparesis, ataxia, visual dysfunction, or cognitive impairment.",
      "key": "eee9be5b7edda482ec99a61c14f8c297",
      "line": 87,
      "relation": "increases",
      "source": 35,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Patients with primary and secondary progressive multiple sclerosis exhibit gradually worsening disability, most often motor impairment with a pattern suggesting a myelopathy, but also progressive hemiparesis, ataxia, visual dysfunction, or cognitive impairment.",
      "key": "69dab053c7032fdd7ba5335c3e471cd2",
      "line": 89,
      "relation": "increases",
      "source": 35,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Patients with primary and secondary progressive multiple sclerosis exhibit gradually worsening disability, most often motor impairment with a pattern suggesting a myelopathy, but also progressive hemiparesis, ataxia, visual dysfunction, or cognitive impairment.",
      "key": "187c92505e54e5ee25466bd3d3ce8575",
      "line": 91,
      "relation": "decreases",
      "source": 35,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Patients with primary and secondary progressive multiple sclerosis exhibit gradually worsening disability, most often motor impairment with a pattern suggesting a myelopathy, but also progressive hemiparesis, ataxia, visual dysfunction, or cognitive impairment.",
      "key": "54ca6de7d29e0768ff900751aa239535",
      "line": 80,
      "relation": "increases",
      "source": 38,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Patients with primary and secondary progressive multiple sclerosis exhibit gradually worsening disability, most often motor impairment with a pattern suggesting a myelopathy, but also progressive hemiparesis, ataxia, visual dysfunction, or cognitive impairment.",
      "key": "1e01fbd6a4d85d32f749bc29a4761bfa",
      "line": 82,
      "relation": "increases",
      "source": 38,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Patients with primary and secondary progressive multiple sclerosis exhibit gradually worsening disability, most often motor impairment with a pattern suggesting a myelopathy, but also progressive hemiparesis, ataxia, visual dysfunction, or cognitive impairment.",
      "key": "9d8d86522a38f99a12dcf2408f66f794",
      "line": 84,
      "relation": "increases",
      "source": 38,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Patients with primary and secondary progressive multiple sclerosis exhibit gradually worsening disability, most often motor impairment with a pattern suggesting a myelopathy, but also progressive hemiparesis, ataxia, visual dysfunction, or cognitive impairment.",
      "key": "230ae57c8b8f6fd8236b10dc9474943f",
      "line": 86,
      "relation": "increases",
      "source": 38,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Patients with primary and secondary progressive multiple sclerosis exhibit gradually worsening disability, most often motor impairment with a pattern suggesting a myelopathy, but also progressive hemiparesis, ataxia, visual dysfunction, or cognitive impairment.",
      "key": "80eb280e23029d57e04a0978062cd1b5",
      "line": 88,
      "relation": "increases",
      "source": 38,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Patients with primary and secondary progressive multiple sclerosis exhibit gradually worsening disability, most often motor impairment with a pattern suggesting a myelopathy, but also progressive hemiparesis, ataxia, visual dysfunction, or cognitive impairment.",
      "key": "d0f3e0ec1711b5f711c1654918cfd63b",
      "line": 90,
      "relation": "increases",
      "source": 38,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Patients with primary and secondary progressive multiple sclerosis exhibit gradually worsening disability, most often motor impairment with a pattern suggesting a myelopathy, but also progressive hemiparesis, ataxia, visual dysfunction, or cognitive impairment.",
      "key": "03c453136aa91368f3b5f043a95ae293",
      "line": 92,
      "relation": "decreases",
      "source": 38,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "In the early stages, pathology is dominated by focal inflammatory lesions with perivenular accumulation of T and B lymphocytes, bloodâbrain barrier disruption, demyelination, and acute axonal transection.[5]",
      "key": "cc1c28c49770da11ad80e9235e019ffa",
      "line": 97,
      "relation": "increases",
      "source": 34,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "In the early stages, pathology is dominated by focal inflammatory lesions with perivenular accumulation of T and B lymphocytes, bloodâbrain barrier disruption, demyelination, and acute axonal transection.[5]",
      "key": "a7174ebde557076f86ecf23fb9e95e8b",
      "line": 98,
      "relation": "increases",
      "source": 34,
      "target": 15
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "In the early stages, pathology is dominated by focal inflammatory lesions with perivenular accumulation of T and B lymphocytes, bloodâbrain barrier disruption, demyelination, and acute axonal transection.[5]",
      "key": "bd03d45a8365d5b0b395691e2dd14fc5",
      "line": 99,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 34,
      "target": 5
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "In the early stages, pathology is dominated by focal inflammatory lesions with perivenular accumulation of T and B lymphocytes, bloodâbrain barrier disruption, demyelination, and acute axonal transection.[5]",
      "key": "f2a6bad88592542dc029ed871273b4ef",
      "line": 100,
      "relation": "increases",
      "source": 34,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "In the early stages, pathology is dominated by focal inflammatory lesions with perivenular accumulation of T and B lymphocytes, bloodâbrain barrier disruption, demyelination, and acute axonal transection.[5]",
      "key": "0b753887be67700bf63866e1cc40a03a",
      "line": 101,
      "relation": "association",
      "source": 34,
      "target": 20
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "progressive relapsing multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "The severity of cortical demyelination correlates with the extent of meningeal inflammation in progressive multiple sclerosis, suggesting a pathogenic role.[10]",
      "key": "d90fdafd190bb2d603e67492bcd056db",
      "line": 126,
      "relation": "positiveCorrelation",
      "source": 40,
      "target": 49
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "In the early stages, pathology is dominated by focal inflammatory lesions with perivenular accumulation of T and B lymphocytes, bloodâbrain barrier disruption, demyelination, and acute axonal transection.[5]",
      "key": "427f8322698d267d61a419f9440e41c5",
      "line": 101,
      "relation": "association",
      "source": 20,
      "target": 34
    },
    {
      "annotations": {
        "Anatomy": {
          "cerebellum": true,
          "cortex": true,
          "spinal cord": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "The clinical importance of grey matter pathology involving cortex, deep structures, cerebellum, and spinal cord is increasingly recognised in progressive multiple sclerosis.[7]",
      "key": "1df100354e96a9df18ab3fdf99735b98",
      "line": 107,
      "relation": "association",
      "source": 36,
      "target": 6
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Cortical histopathology includes microglial activation, demyelination, neuritic transection, neuronal death, and reduced presynaptic terminals, but tends not to include perivascular lymphocytic cuffs typical of white matter lesions.[8]",
      "key": "3ca1052cf0ac4341a920045c6b37013d",
      "line": 114,
      "relation": "increases",
      "source": 36,
      "target": 16
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Cortical histopathology includes microglial activation, demyelination, neuritic transection, neuronal death, and reduced presynaptic terminals, but tends not to include perivascular lymphocytic cuffs typical of white matter lesions.[8]",
      "key": "80cd5c2c91414901dc4ca170c1de9c20",
      "line": 115,
      "relation": "increases",
      "source": 36,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Cortical histopathology includes microglial activation, demyelination, neuritic transection, neuronal death, and reduced presynaptic terminals, but tends not to include perivascular lymphocytic cuffs typical of white matter lesions.[8]",
      "key": "8d5461d1137c920f51848f77f99f68ac",
      "line": 116,
      "relation": "association",
      "source": 36,
      "target": 10
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Cortical histopathology includes microglial activation, demyelination, neuritic transection, neuronal death, and reduced presynaptic terminals, but tends not to include perivascular lymphocytic cuffs typical of white matter lesions.[8]",
      "key": "daa8c4f702317ae8b012ef91f4ab8f14",
      "line": 118,
      "relation": "increases",
      "source": 36,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Cortical histopathology includes microglial activation, demyelination, neuritic transection, neuronal death, and reduced presynaptic terminals, but tends not to include perivascular lymphocytic cuffs typical of white matter lesions.[8]",
      "key": "beaf701539a5626df3348472c593c7c5",
      "line": 120,
      "relation": "decreases",
      "source": 36,
      "target": 7
    },
    {
      "annotations": {
        "CellStructure": {
          "Axons": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Demyelinated axons are abundant in longstanding multiple sclerosis and are hypothesised to be susceptible to chronic injury.[6]",
      "key": "82a6880d1901ad08cc5d61d9ed4d0dbb",
      "line": 134,
      "relation": "increases",
      "source": 36,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Caudate Nucleus": true,
          "Hippocampus": true,
          "Thalamus": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Atrophy of deep grey structures (thalamus, caudate, and hippocampus) also occurs in progressive multiple sclerosis and can be focal (presumably due to lesions) or more diffuse (presumably due to damage to afferent or efferent connections).[29,30]",
      "key": "199ab01c974a3d6919dd83a5a291646a",
      "line": 180,
      "relation": "increases",
      "source": 36,
      "target": 48
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis, Relapsing-Remitting": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Cellular energy metabolism seems to be abnormal in progressive multiple sclerosis [11] and is another potential therapeutic target.",
      "key": "c22f44f214e25699a03cf162006016aa",
      "line": 206,
      "relation": "negativeCorrelation",
      "source": 36,
      "target": 22
    },
    {
      "annotations": {
        "Anatomy": {
          "cerebellum": true,
          "cortex": true,
          "spinal cord": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "The clinical importance of grey matter pathology involving cortex, deep structures, cerebellum, and spinal cord is increasingly recognised in progressive multiple sclerosis.[7]",
      "key": "51ea0447be4265f41c58283c604d1430",
      "line": 107,
      "relation": "association",
      "source": 6,
      "target": 36
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Cortical histopathology includes microglial activation, demyelination, neuritic transection, neuronal death, and reduced presynaptic terminals, but tends not to include perivascular lymphocytic cuffs typical of white matter lesions.[8]",
      "key": "811695b1c2320d0ea06e1e5a9324572a",
      "line": 116,
      "relation": "association",
      "source": 10,
      "target": 36
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "progressive relapsing multiple sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "The severity of cortical demyelination correlates with the extent of meningeal inflammation in progressive multiple sclerosis, suggesting a pathogenic role.[10]",
      "key": "95349f18b4eb7ea8810262d689a0ddec",
      "line": 126,
      "relation": "positiveCorrelation",
      "source": 49,
      "target": 40
    },
    {
      "annotations": {
        "CellStructure": {
          "Axons": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "In some demyelinated axons, saltatory nerve-impulse conduction is replaced by continuous conduction, which restores function but increases energy demand and sodium accumulation in the axonal cytoplasm. Resultant reverse operation of sodiumâcalcium exchanger to restore ionic gradients could lead to cytoplasmic calcium accumulation, activation of calpains, and proteolysis of cytoskeleton.",
      "key": "6b8a1d669a3cf8219fe88d926ed0e969",
      "line": 139,
      "relation": "association",
      "source": 51,
      "target": 23
    },
    {
      "annotations": {
        "CellStructure": {
          "Axons": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "In some demyelinated axons, saltatory nerve-impulse conduction is replaced by continuous conduction, which restores function but increases energy demand and sodium accumulation in the axonal cytoplasm. Resultant reverse operation of sodiumâcalcium exchanger to restore ionic gradients could lead to cytoplasmic calcium accumulation, activation of calpains, and proteolysis of cytoskeleton.",
      "key": "a501e86809a61dc7466cc0bae32a1e18",
      "line": 140,
      "relation": "increases",
      "source": 51,
      "target": 22
    },
    {
      "annotations": {
        "CellStructure": {
          "Axons": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "In some demyelinated axons, saltatory nerve-impulse conduction is replaced by continuous conduction, which restores function but increases energy demand and sodium accumulation in the axonal cytoplasm. Resultant reverse operation of sodiumâcalcium exchanger to restore ionic gradients could lead to cytoplasmic calcium accumulation, activation of calpains, and proteolysis of cytoskeleton.",
      "key": "8bfad53e1b6bdd816b058f96c1a93bc5",
      "line": 141,
      "object": {
        "location": {
          "name": "axon cytoplasm",
          "namespace": "GO"
        }
      },
      "relation": "increases",
      "source": 51,
      "target": 13
    },
    {
      "annotations": {
        "CellStructure": {
          "Axons": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "In some demyelinated axons, saltatory nerve-impulse conduction is replaced by continuous conduction, which restores function but increases energy demand and sodium accumulation in the axonal cytoplasm. Resultant reverse operation of sodiumâcalcium exchanger to restore ionic gradients could lead to cytoplasmic calcium accumulation, activation of calpains, and proteolysis of cytoskeleton.",
      "key": "939bee430d300936dadc9d59cc1e0f80",
      "line": 139,
      "relation": "association",
      "source": 23,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis, Relapsing-Remitting": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Cellular energy metabolism seems to be abnormal in progressive multiple sclerosis [11] and is another potential therapeutic target.",
      "key": "03f9e7914112aee240ac8b06a3d88725",
      "line": 206,
      "relation": "negativeCorrelation",
      "source": 22,
      "target": 36
    },
    {
      "annotations": {
        "CellStructure": {
          "Axons": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "In some demyelinated axons, saltatory nerve-impulse conduction is replaced by continuous conduction, which restores function but increases energy demand and sodium accumulation in the axonal cytoplasm. Resultant reverse operation of sodiumâcalcium exchanger to restore ionic gradients could lead to cytoplasmic calcium accumulation, activation of calpains, and proteolysis of cytoskeleton.",
      "key": "34f7b33612a5622cd9a40d3f691a38f1",
      "line": 142,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 13,
      "subject": {
        "location": {
          "name": "axon cytoplasm",
          "namespace": "GO"
        }
      },
      "target": 31
    },
    {
      "key": "e36587ab9872d2d784c81d9a78ead04d",
      "relation": "partOf",
      "source": 13,
      "target": 27
    },
    {
      "key": "cdc989a5b67e3e7e621951fb257db6d3",
      "relation": "partOf",
      "source": 31,
      "target": 27
    },
    {
      "annotations": {
        "CellStructure": {
          "Axons": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "In some demyelinated axons, saltatory nerve-impulse conduction is replaced by continuous conduction, which restores function but increases energy demand and sodium accumulation in the axonal cytoplasm. Resultant reverse operation of sodiumâcalcium exchanger to restore ionic gradients could lead to cytoplasmic calcium accumulation, activation of calpains, and proteolysis of cytoskeleton.",
      "key": "7a77334dceeb19c322be973da35da4ab",
      "line": 143,
      "object": {
        "location": {
          "name": "axon cytoplasm",
          "namespace": "GO"
        }
      },
      "relation": "increases",
      "source": 27,
      "target": 0
    },
    {
      "annotations": {
        "CellStructure": {
          "Axons": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "In some demyelinated axons, saltatory nerve-impulse conduction is replaced by continuous conduction, which restores function but increases energy demand and sodium accumulation in the axonal cytoplasm. Resultant reverse operation of sodiumâcalcium exchanger to restore ionic gradients could lead to cytoplasmic calcium accumulation, activation of calpains, and proteolysis of cytoskeleton.",
      "key": "0ce75351eea62829a739454303f240e8",
      "line": 144,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 0,
      "subject": {
        "location": {
          "name": "axon cytoplasm",
          "namespace": "GO"
        }
      },
      "target": 30
    },
    {
      "annotations": {
        "CellStructure": {
          "Axons": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "In some demyelinated axons, saltatory nerve-impulse conduction is replaced by continuous conduction, which restores function but increases energy demand and sodium accumulation in the axonal cytoplasm. Resultant reverse operation of sodiumâcalcium exchanger to restore ionic gradients could lead to cytoplasmic calcium accumulation, activation of calpains, and proteolysis of cytoskeleton.",
      "key": "b4a6d6102cedccf64a08ba228f1f95ab",
      "line": 146,
      "relation": "decreases",
      "source": 0,
      "subject": {
        "location": {
          "name": "axon cytoplasm",
          "namespace": "GO"
        }
      },
      "target": 4
    },
    {
      "annotations": {
        "CellStructure": {
          "Axons": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "In some demyelinated axons, saltatory nerve-impulse conduction is replaced by continuous conduction, which restores function but increases energy demand and sodium accumulation in the axonal cytoplasm. Resultant reverse operation of sodiumâcalcium exchanger to restore ionic gradients could lead to cytoplasmic calcium accumulation, activation of calpains, and proteolysis of cytoskeleton.",
      "key": "8b9519656deebaf09623f7329b6fea78",
      "line": 145,
      "relation": "decreases",
      "source": 30,
      "subject": {
        "modifier": "Activity"
      },
      "target": 4
    },
    {
      "annotations": {
        "CellStructure": {
          "Axons": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Mitochondrial dysfunction in axons seems to result from impaired mitochondrial transport, susceptibility to oxidative injury, and mutations in mitochondrial DNA, all of which lead to impaired energy production and generation of reactive oxygen species.",
      "key": "8bd7273c0b168c825e6d08a1bd13831c",
      "line": 151,
      "relation": "negativeCorrelation",
      "source": 17,
      "target": 32
    },
    {
      "annotations": {
        "CellStructure": {
          "Axons": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Mitochondrial dysfunction in axons seems to result from impaired mitochondrial transport, susceptibility to oxidative injury, and mutations in mitochondrial DNA, all of which lead to impaired energy production and generation of reactive oxygen species.",
      "key": "b80df944bef702ae2f04aa379af38112",
      "line": 151,
      "relation": "negativeCorrelation",
      "source": 32,
      "target": 17
    },
    {
      "annotations": {
        "CellStructure": {
          "Axons": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Mitochondrial dysfunction in axons seems to result from impaired mitochondrial transport, susceptibility to oxidative injury, and mutations in mitochondrial DNA, all of which lead to impaired energy production and generation of reactive oxygen species.",
      "key": "0dd9bf57cdfc08fd6d7f7c31ae2f2779",
      "line": 152,
      "relation": "increases",
      "source": 32,
      "target": 46
    },
    {
      "annotations": {
        "CellStructure": {
          "Axons": true,
          "Mitochondria": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Mitochondrial dysfunction in axons seems to result from impaired mitochondrial transport, susceptibility to oxidative injury, and mutations in mitochondrial DNA, all of which lead to impaired energy production and generation of reactive oxygen species.",
      "key": "3368a3fe8221de9bb60ace33dbb787e9",
      "line": 155,
      "relation": "increases",
      "source": 32,
      "target": 44
    },
    {
      "annotations": {
        "CellStructure": {
          "Axons": true,
          "Mitochondria": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Mitochondrial dysfunction in axons seems to result from impaired mitochondrial transport, susceptibility to oxidative injury, and mutations in mitochondrial DNA, all of which lead to impaired energy production and generation of reactive oxygen species.",
      "key": "cf9321960087a0681b8d874aba7f754f",
      "line": 156,
      "relation": "decreases",
      "source": 44,
      "target": 22
    },
    {
      "annotations": {
        "CellStructure": {
          "Axons": true,
          "Mitochondria": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Mitochondrial dysfunction in axons seems to result from impaired mitochondrial transport, susceptibility to oxidative injury, and mutations in mitochondrial DNA, all of which lead to impaired energy production and generation of reactive oxygen species.",
      "key": "db832802846f371140ded09cd176e349",
      "line": 157,
      "relation": "increases",
      "source": 44,
      "target": 8
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Whole-brain atrophy correlates with physical [20] and cognitive [21] impairment.",
      "key": "e3633ce93bf5c59ef8d1c11417fb7e67",
      "line": 164,
      "relation": "decreases",
      "source": 48,
      "target": 18
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true,
          "cortex": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Cortical atrophy is prominent in progressive multiple sclerosis [26] and correlates with physical [27] and cognitive [28] impairment.",
      "key": "aa0854e3c68b17ba6ff376ae5e66ac1f",
      "line": 172,
      "relation": "decreases",
      "source": 48,
      "target": 18
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Whole-brain atrophy correlates with physical [20] and cognitive [21] impairment.",
      "key": "808cc8488c4796a22507609b4d2943c3",
      "line": 165,
      "relation": "increases",
      "source": 48,
      "target": 45
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true,
          "cortex": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Cortical atrophy is prominent in progressive multiple sclerosis [26] and correlates with physical [27] and cognitive [28] impairment.",
      "key": "c6afe7a999ae370e1001d4920a202211",
      "line": 173,
      "relation": "increases",
      "source": 48,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Spinal Cord": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Spinal cord atrophy correlates with clinical measures of disability.[35]",
      "key": "eefede542cc1d69c4a3b32c551dee605",
      "line": 187,
      "relation": "increases",
      "source": 48,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis, Relapsing-Remitting": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Fingolimod reduced relapses, MRI lesion activity, and brain volume loss in three phase 3 trials in relapsing-remitting multiple sclerosis.[56â58]",
      "key": "5b7fea97a7531f07a600e64de2bb50eb",
      "line": 195,
      "relation": "decreases",
      "source": 3,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis, Relapsing-Remitting": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Fingolimod reduced relapses, MRI lesion activity, and brain volume loss in three phase 3 trials in relapsing-remitting multiple sclerosis.[56â58]",
      "key": "85534df08cdcb19a7db51c4655c4e573",
      "line": 196,
      "relation": "decreases",
      "source": 3,
      "target": 53
    },
    {
      "key": "02dc2a65521964be0f3de36cbceb72d3",
      "relation": "partOf",
      "source": 3,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis, Relapsing-Remitting": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Fingolimod readily enters the brain and has direct effects on several CNS cell types mediated by sphingosine 1-phosphate receptors, suggesting it might be beneficial in progressive multiple sclerosis.[59]",
      "key": "4cb79284cf6e60038dc1322e3b8cc263",
      "line": 201,
      "relation": "association",
      "source": 26,
      "target": 37
    },
    {
      "key": "4ed6a94c05a87e96d3bbcc95cc9f6ff9",
      "relation": "partOf",
      "source": 29,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis, Relapsing-Remitting": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "Fingolimod readily enters the brain and has direct effects on several CNS cell types mediated by sphingosine 1-phosphate receptors, suggesting it might be beneficial in progressive multiple sclerosis.[59]",
      "key": "b19a15d06a5190c9a6f96ce1eafbcdaa",
      "line": 201,
      "relation": "association",
      "source": 37,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis, Relapsing-Remitting": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "The vitamin biotin is a coenzyme for many essential carboxylases and, in high doses, is hypothesised to enhance cellular energy production with resultant improved axonal function, decreased neurodegeneration, and enhanced remyelination.[65]",
      "key": "07975d167ce8a606fd4887027f86c4bf",
      "line": 211,
      "relation": "increases",
      "source": 1,
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis, Relapsing-Remitting": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "The vitamin biotin is a coenzyme for many essential carboxylases and, in high doses, is hypothesised to enhance cellular energy production with resultant improved axonal function, decreased neurodegeneration, and enhanced remyelination.[65]",
      "key": "30049635fc7e230099a4f3bd0c87efc5",
      "line": 212,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 1,
      "target": 9
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis, Relapsing-Remitting": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "The vitamin biotin is a coenzyme for many essential carboxylases and, in high doses, is hypothesised to enhance cellular energy production with resultant improved axonal function, decreased neurodegeneration, and enhanced remyelination.[65]",
      "key": "59e4f611e52fd0b052e2d82e23e77cce",
      "line": 213,
      "relation": "decreases",
      "source": 1,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis, Relapsing-Remitting": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "The vitamin biotin is a coenzyme for many essential carboxylases and, in high doses, is hypothesised to enhance cellular energy production with resultant improved axonal function, decreased neurodegeneration, and enhanced remyelination.[65]",
      "key": "6b783db736e7106bf8da1e1f836e356e",
      "line": 214,
      "relation": "increases",
      "source": 1,
      "target": 25
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis, Relapsing-Remitting": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "LINGO-1 is a protein expressed by oligodendrocytes and neurons that inhibits remyelination.[66]",
      "key": "4229c26278ca1b2b543283feec9395ea",
      "line": 219,
      "relation": "increases",
      "source": 12,
      "target": 28
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis, Relapsing-Remitting": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "LINGO-1 is a protein expressed by oligodendrocytes and neurons that inhibits remyelination.[66]",
      "key": "e9c9316b0664b91e249fd48a1255b4c5",
      "line": 221,
      "relation": "increases",
      "source": 12,
      "target": 25
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis, Relapsing-Remitting": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "LINGO-1 is a protein expressed by oligodendrocytes and neurons that inhibits remyelination.[66]",
      "key": "a5322f5cdea0b0ae50d6da3a2c0ae77f",
      "line": 220,
      "relation": "increases",
      "source": 11,
      "target": 28
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis, Relapsing-Remitting": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "LINGO-1 is a protein expressed by oligodendrocytes and neurons that inhibits remyelination.[66]",
      "key": "b0b863bb34b88775610e1b00da47e98d",
      "line": 222,
      "relation": "increases",
      "source": 11,
      "target": 25
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "A pilot study of clemastine showed improvement on visual evoked potentials in participants with multiple sclerosis-related chronic optic neuropathy.[73]",
      "key": "10dca13c61dbd5ff2bec3f1cea4ba527",
      "line": 228,
      "relation": "increases",
      "source": 2,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHDisease": {
          "Multiple Sclerosis": true
        }
      },
      "citation": {
        "authors": [
          "Brownlee WJ",
          "Fazekas F",
          "Hardy TA",
          "Miller DH"
        ],
        "date": "2017-04-01",
        "db": "PubMed",
        "db_id": "27889190",
        "db_name": "Diagnosis of multiple sclerosis: progress and challenges.",
        "first": "Brownlee WJ",
        "journal": "Lancet (London, England)",
        "last": "Miller DH",
        "pages": "1336-1346",
        "volume": "389"
      },
      "evidence": "A pilot study of clemastine showed improvement on visual evoked potentials in participants with multiple sclerosis-related chronic optic neuropathy.[73]",
      "key": "e273a4a831d8ed34ec73871cfaba73e7",
      "line": 229,
      "relation": "increases",
      "source": 2,
      "target": 19
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"calcium cation\")",
      "concept": {
        "name": "calcium cation",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "843ecb28e813dc0ee53e75bc5c86e613"
    },
    {
      "bel": "a(CHEBI:biotin)",
      "concept": {
        "name": "biotin",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "c0a2eff81e9acad15eadaf9f20b03bf3"
    },
    {
      "bel": "a(DRUGBANK:Clemastine)",
      "concept": {
        "name": "Clemastine",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "20333e3bbad007ae2a71316f68586203"
    },
    {
      "bel": "a(DRUGBANK:Fingolimod)",
      "concept": {
        "name": "Fingolimod",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "de33bded27be2c6871c8e342da56fc38"
    },
    {
      "bel": "a(GO:cytoskeleton)",
      "concept": {
        "name": "cytoskeleton",
        "namespace": "GO"
      },
      "function": "Abundance",
      "id": "51ad31d28e474c33008791d4c056bf13"
    },
    {
      "bel": "a(MESH:\"Blood-Brain Barrier\")",
      "concept": {
        "name": "Blood-Brain Barrier",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "63dcf0f7f45e2c3862eb5a77da5f2627"
    },
    {
      "bel": "a(MESH:\"Gray Matter\")",
      "concept": {
        "name": "Gray Matter",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "ec3d8cd3fe21e400949f6f15da400cd6"
    },
    {
      "bel": "a(MESH:\"Presynaptic Terminals\")",
      "concept": {
        "name": "Presynaptic Terminals",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "f933852454994d439499af0b968da5b8"
    },
    {
      "bel": "a(MESH:\"Reactive Oxygen Species\")",
      "concept": {
        "name": "Reactive Oxygen Species",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "dd0e798c738472fa8ffb9fa88a2eacc7"
    },
    {
      "bel": "a(MESH:Axons)",
      "concept": {
        "name": "Axons",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "438b15a6e68338bcf5615b067cf5d271"
    },
    {
      "bel": "a(MESH:Neurites)",
      "concept": {
        "name": "Neurites",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "192f89a6158de53e2d132cdabb1553da"
    },
    {
      "bel": "a(MESH:Neurons)",
      "concept": {
        "name": "Neurons",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "c429b8780142c504cf23cacfc2fa2b09"
    },
    {
      "bel": "a(MESH:Oligodendroglia)",
      "concept": {
        "name": "Oligodendroglia",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "828404c8a29719c3b6437908364a6ddd"
    },
    {
      "bel": "a(MESH:Sodium)",
      "concept": {
        "name": "Sodium",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "9b2c5dccd06f60600bf4e1ecb40cbaea"
    },
    {
      "bel": "bp(GO:\"B cell activation\")",
      "concept": {
        "name": "B cell activation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "b8c0c901f2d5cd6008437d007903dccb"
    },
    {
      "bel": "bp(GO:\"T cell activation\")",
      "concept": {
        "name": "T cell activation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "6475795284a1f1c537342febd590bb31"
    },
    {
      "bel": "bp(GO:\"microglial cell activation\")",
      "concept": {
        "name": "microglial cell activation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "3c02f523866973a040dc6bfa5b372b2e"
    },
    {
      "bel": "bp(GO:\"mitochondrial transport\")",
      "concept": {
        "name": "mitochondrial transport",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "fe54bc53eaa9419f7d3745d6f65201bf"
    },
    {
      "bel": "bp(GO:cognition)",
      "concept": {
        "name": "cognition",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "24220ec2073c35bcd945681ee9c6ea38"
    },
    {
      "bel": "bp(HP:\"Optic neuropathy\")",
      "concept": {
        "name": "Optic neuropathy",
        "namespace": "HP"
      },
      "function": "BiologicalProcess",
      "id": "6fc877cd096a5654678489b6fb82f2e0"
    },
    {
      "bel": "bp(MESH:\"Axonal Transport\")",
      "concept": {
        "name": "Axonal Transport",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "d04aee60fa1a8ead109b6583c1b4e711"
    },
    {
      "bel": "bp(MESH:\"Cell Death\")",
      "concept": {
        "name": "Cell Death",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "fdcf9ec5fc3c984c45cd62abeab40dc0"
    },
    {
      "bel": "bp(MESH:\"Energy Metabolism\")",
      "concept": {
        "name": "Energy Metabolism",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "5aaa959e5040d4765b684841ad0942e1"
    },
    {
      "bel": "bp(MESH:\"Neural Conduction\")",
      "concept": {
        "name": "Neural Conduction",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "85d7660e247fcbcf3c463be4a1810d4a"
    },
    {
      "bel": "bp(MESH:\"Vision, Ocular\")",
      "concept": {
        "name": "Vision, Ocular",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "b2d2eeef24c19bd5e81b58eb4b551a74"
    },
    {
      "bel": "bp(MESH:Remyelination)",
      "concept": {
        "name": "Remyelination",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "79abdcab21f9bd75b3078b78620119b0"
    },
    {
      "bel": "complex(a(DRUGBANK:Fingolimod), p(HGNCGENEFAMILY:\"Sphingosine 1-phosphate receptors\"))",
      "function": "Complex",
      "id": "2741d3454539bb09faeb9b5795a36fe4",
      "members": [
        {
          "bel": "a(DRUGBANK:Fingolimod)",
          "concept": {
            "name": "Fingolimod",
            "namespace": "DRUGBANK"
          },
          "function": "Abundance",
          "id": "de33bded27be2c6871c8e342da56fc38"
        },
        {
          "bel": "p(HGNCGENEFAMILY:\"Sphingosine 1-phosphate receptors\")",
          "concept": {
            "name": "Sphingosine 1-phosphate receptors",
            "namespace": "HGNCGENEFAMILY"
          },
          "function": "Protein",
          "id": "e1d36600ec3ae163d5c1f044a7eae6ee"
        }
      ]
    },
    {
      "bel": "composite(a(MESH:Sodium), p(MESH:\"Sodium-Calcium Exchanger\"))",
      "function": "Composite",
      "id": "178baa049fae0993df122c2e0b5495b8",
      "members": [
        {
          "bel": "a(MESH:Sodium)",
          "concept": {
            "name": "Sodium",
            "namespace": "MESH"
          },
          "function": "Abundance",
          "id": "9b2c5dccd06f60600bf4e1ecb40cbaea"
        },
        {
          "bel": "p(MESH:\"Sodium-Calcium Exchanger\")",
          "concept": {
            "name": "Sodium-Calcium Exchanger",
            "namespace": "MESH"
          },
          "function": "Protein",
          "id": "34b7b8e6e01ecbc80f57cfbe123a4fbc"
        }
      ]
    },
    {
      "bel": "p(HGNC:LINGO1)",
      "concept": {
        "name": "LINGO1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "5293ae73db034f03a25a047ae2a76e4c"
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Sphingosine 1-phosphate receptors\")",
      "concept": {
        "name": "Sphingosine 1-phosphate receptors",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "e1d36600ec3ae163d5c1f044a7eae6ee"
    },
    {
      "bel": "p(HGNCGENEFAMILY:Calpains)",
      "concept": {
        "name": "Calpains",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "7ca722526fc0d17a88d8dc58f35706a6"
    },
    {
      "bel": "p(MESH:\"Sodium-Calcium Exchanger\")",
      "concept": {
        "name": "Sodium-Calcium Exchanger",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "34b7b8e6e01ecbc80f57cfbe123a4fbc"
    },
    {
      "bel": "path(CONSO:\"mitochondrial dysfunction\")",
      "concept": {
        "name": "mitochondrial dysfunction",
        "namespace": "CONSO"
      },
      "function": "Pathology",
      "id": "14a330b2e354b7af4f380b05664a5728"
    },
    {
      "bel": "path(CONSO:Neurodegeneration)",
      "concept": {
        "name": "Neurodegeneration",
        "namespace": "CONSO"
      },
      "function": "Pathology",
      "id": "e18248b0d7323caa29b448e45437a1e5"
    },
    {
      "bel": "path(DOID:\"multiple sclerosis\")",
      "concept": {
        "name": "multiple sclerosis",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "828e65d53fe5c29b364f79cfd5304f90"
    },
    {
      "bel": "path(DOID:\"primary progressive multiple sclerosis\")",
      "concept": {
        "name": "primary progressive multiple sclerosis",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "bc354c4df683e76d8f33dad953c46827"
    },
    {
      "bel": "path(DOID:\"progressive relapsing multiple sclerosis\")",
      "concept": {
        "name": "progressive relapsing multiple sclerosis",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "6911d1dc25a970713114a8a92f038cbe"
    },
    {
      "bel": "path(DOID:\"relapsing-remitting multiple sclerosis\")",
      "concept": {
        "name": "relapsing-remitting multiple sclerosis",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "b21b34dd5c948d6330eceb5f4eb9649f"
    },
    {
      "bel": "path(DOID:\"secondary progressive multiple sclerosis\")",
      "concept": {
        "name": "secondary progressive multiple sclerosis",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "38f0567d9ceb0ade6bf93de56a897396"
    },
    {
      "bel": "path(GO:cognition)",
      "concept": {
        "name": "cognition",
        "namespace": "GO"
      },
      "function": "Pathology",
      "id": "1c1714014427bf1244c4bc1ec777b694"
    },
    {
      "bel": "path(HP:\"CNS demyelination\")",
      "concept": {
        "name": "CNS demyelination",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "fb7670f43e6511eda6fbd0b0517820a6"
    },
    {
      "bel": "path(HP:Ataxia)",
      "concept": {
        "name": "Ataxia",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "da410da3fc48fdd33615f068787f9705"
    },
    {
      "bel": "path(HP:Hemiparesis)",
      "concept": {
        "name": "Hemiparesis",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "9abd8c6c941cad4d9ecf8178e74ccfd4"
    },
    {
      "bel": "path(HP:Myelopathy)",
      "concept": {
        "name": "Myelopathy",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "0e8e666aba2c122916e2509d0a34946d"
    },
    {
      "bel": "path(MESH:\"DNA Damage\")",
      "concept": {
        "name": "DNA Damage",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "21c7af2e646347699cc2f61cb7ab8225"
    },
    {
      "bel": "path(MESH:\"Motor Disorders\")",
      "concept": {
        "name": "Motor Disorders",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "2e3b041e894813b580bde665989837d0"
    },
    {
      "bel": "path(MESH:\"Oxidative Stress\")",
      "concept": {
        "name": "Oxidative Stress",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "5d5071d9dea362c9b9b6ee5de9eb67be"
    },
    {
      "bel": "path(MESH:\"Vision Disorders\")",
      "concept": {
        "name": "Vision Disorders",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "83a250aaf35ebb80bc12673253363fb5"
    },
    {
      "bel": "path(MESH:Atrophy)",
      "concept": {
        "name": "Atrophy",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "7d5394b2784c6e661c25500d859dc266"
    },
    {
      "bel": "path(MESH:Meningitis)",
      "concept": {
        "name": "Meningitis",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "de1b8fae2c3475b6d223ff0982fea7bf"
    },
    {
      "bel": "path(MESH:Recurrence)",
      "concept": {
        "name": "Recurrence",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "aa96a379e06d692c47a017c1b23ad98f"
    },
    {
      "bel": "path(NCIT:C117277)",
      "concept": {
        "name": "C117277",
        "namespace": "NCIT"
      },
      "function": "Pathology",
      "id": "24ca02ad1b4993ba4c5c0242df655c6d"
    },
    {
      "bel": "path(NCIT:C21007)",
      "concept": {
        "name": "C21007",
        "namespace": "NCIT"
      },
      "function": "Pathology",
      "id": "567e9969f4afcd1025c406a11302125a"
    },
    {
      "bel": "path(NCIT:C3824)",
      "concept": {
        "name": "C3824",
        "namespace": "NCIT"
      },
      "function": "Pathology",
      "id": "ff31f470d2de26c1af1f1301d4a050d0"
    }
  ]
}